Cardiology

Top Story

Antisense oligonucleotide associated with substantial reductions in Lp(a) concentrations

Antisense oligonucleotide associated with substantial reductions in Lp(a) concentrations
September 26, 2016

A novel antisense oligonucleotide targeting apolipoprotein(a) was safe and conferred a decline in concentrations of lipoprotein(a), according to findings published in The Lancet.

Researcher Sotirios Tsimikas, MD, told Cardiology Today that there is no approved therapy for reduction of Lp(a), and reducing it may make an impact on the components of CVD risk not currently addressed by available therapies and lifestyle modifications.

In the Journals

Transcatheter pulmonary valve replacement reduces tricuspid regurgitation for certain patients

September 26, 2016
In patients with postoperative right ventricular outflow tract conduit dysfunction and significant baseline tricuspid regurgitation, transcatheter pulmonary valve…
In the Journals

Physicians debate ACGME's Milestones initiative

September 26, 2016
The Accreditation Council for Graduate Medical Education’s Milestones initiative and its role in internal medicine are a source of debate for physicians. …

Trial of MST-188 in sickle cell disease fails to meet primary endpoint

September 26, 2016
A randomized phase 3 trial designed to evaluate the investigational drug vepoloxamer failed to meet its primary endpoint of significantly reducing the mean duration of…
Meeting News CoveragePerspective

At 3 years, patients with acute aortic dissection continue to benefit from stent graft

September 26, 2016
LAS VEGAS — Patients with acute complicated type B aortic dissection mostly had good outcomes at 3 years, according to results presented at VIVA 16. The DISSECTION…
More News Headlines »
morganatic-roan
morganatic-roan